ArticleGeroScience2026
Multimodal prediction of MCI-to-dementia conversion over a two-year window.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Mild cognitive impairment (MCI) represents a heterogeneous clinical state where some individuals remain stable while others progress to dementia. Identification of patients who are at high risk for near-term conversion remains a critical challenge for timely intervention. We developed an explainable multimodal machine-learning framework to predict progression from MCI to dementia within a clinically meaningful two-year period. We analyzed 2008 samples from 828 unique MCI subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI), including cognitive/functional assessments, demographic/genetic variables, and structural MRI features. Subjects were classified as stable MCI (sMCI, n = 1306) or progressive MCI (pMCI, n = 702) based on two-year outcomes. Machine learning algorithms were evaluated on unimodal and multimodal using nested cross-validation, and explainability was assessed using SHapley Additive exPlanations (SHAP) and permutation feature importance. The combination of cognitive assessments, demographics/risk factors and structural MRI features outperformed individual modalities, highlighting the complementary relationship between cognitive-functional decline and neuroanatomical degeneration. The best-performing model, a calibrated XGBoost, achieved a balanced accuracy of 81.28% ± 2.56% during cross-validation and 81.99% (bootstrap mean 81.97%, 95% CI: [78.22%-85.51%]) on an independent held-out test set. Explainable AI analyses identified functional impairment measures (Functional Activities Questionnaire, Clinical Dementia Rating - Sum of Boxes), cognitive performance scores (Alzheimer's Disease Assessment Scale - Cognitive Subscale 11-item version, Alzheimer's Disease Assessment Scale - Cognitive Subscale 13-item version, Mental State Examination), APOE ε4 status, and structural abnormalities within the hippocampus, lateral ventricle, parietal and temporal regions, and amygdala, as the most influential predictors of conversion. Short-term progression from MCI to dementia can be predicted with high accuracy using multimodal information obtained from a single clinical visit. The convergence of cognitive impairment and region-specific neurodegeneration emerged as the strongest indicator of conversion risk.
Indexed as
Identifiers
42768165What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.